Budd-Chiari syndrome primary prevention: Difference between revisions
Jump to navigation
Jump to search
Mazia Fatima (talk | contribs) |
Mazia Fatima (talk | contribs) |
||
Line 11: | Line 11: | ||
*Effective treatment of predisposing conditions | *Effective treatment of predisposing conditions | ||
*Chronic anticoagulation in patients with underlying hypercoagulable disorder | *Chronic anticoagulation in patients with underlying hypercoagulable disorder | ||
*Treat patients with an underlying myeloproliferative disorder with aspirin and hydroxyurea rather than anticoagulants such as warfarin. | |||
==References== | ==References== |
Revision as of 21:21, 8 November 2017
Budd-Chiari syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Budd-Chiari syndrome primary prevention On the Web |
American Roentgen Ray Society Images of Budd-Chiari syndrome primary prevention |
Risk calculators and risk factors for Budd-Chiari syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Primary Prevention
Measures for the primary prevention of Budd-Chiari syndrome include:
- Effective treatment of predisposing conditions
- Chronic anticoagulation in patients with underlying hypercoagulable disorder
- Treat patients with an underlying myeloproliferative disorder with aspirin and hydroxyurea rather than anticoagulants such as warfarin.